Zydus Lifesciences Share Price in Focus: Board to Consider Fund Raise Upto ₹5,000 Crore on November 6

Zydus Lifesciences has scheduled a board meeting on November 6, 2025, to discuss a proposal for raising up to ₹5,000 crore. The company informed the stock exchanges that the funds could be raised through qualified institutional placement (QIP), rights issue, preferential allotment, private placement, or a combination of these methods.

Fundraising and Shareholder Approval

The board will also consider starting a postal ballot process to seek shareholder approval for the proposed fundraising. No details have been shared yet on how the funds will be utilised. Such approvals are a standard procedure for companies exploring capital-raising options to support operations, expansion, or balance sheet management.

Zydus Lifescience Q1FY26 Earnings Results

In the April-June quarter (Q1 FY25), Zydus Lifesciences reported a 3.3% rise in net profit to ₹1,467 crore, mainly supported by a forex gain of ₹57 crore. Revenue during the period stood at ₹6,574 crore, up 6% year-on-year. The company’s EBITDA was flat at ₹2,089 crore, and EBITDA margins declined by about 200 basis points, from 33.6% a year ago to 31.8%.

Upcoming Financial Results

The company is expected to announce its July-September quarter (Q2 FY25) results on the same day as the board meeting, November 6. This will provide a clearer picture of its financial performance for the first half of the fiscal year.

Zydus Lifesciences Share Price Performance 

As of  November 4, 2025, 10:04 AM, Zydus Lifesciences share price was trading at ₹981.70, a 0.06% increase from the previous close.

Read More: Gland Pharma Reports ₹184 Crore Net Profit in Q2 FY26; Revenue Up 5.8%!

Conclusion

Zydus Lifesciences’ upcoming board meeting will focus on both the fundraising proposal and the quarterly results. These developments will outline the company’s financial direction for the coming quarters and its approach to future capital requirements.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.